| Literature DB >> 27142076 |
Wei-Ming Chen1,2,3, Kuo-Liang Wei4,5, Yi-Shing Chen1, Pey-Jium Chang2, Shui-Yi Tung1,3, Te-Sheng Chang1,2, Hao-Chun Huang1, Chein-Heng Shen1,2, Yung-Yu Hsieh1, Cheng-Shyong Wu1,3.
Abstract
BACKGROUND: Tissue sampling for biliary stricture is important for differential diagnosis and further treatment. This study aims to assess the differences of transpapillary biliary biopsy for malignant biliary strictures between cholangiocarcinoma and pancreatic cancer.Entities:
Keywords: Biliary biopsy; Biliary stricture; Cholangiocarcinoma; Pancreatic cancer
Mesh:
Year: 2016 PMID: 27142076 PMCID: PMC4855757 DOI: 10.1186/s12957-016-0883-8
Source DB: PubMed Journal: World J Surg Oncol ISSN: 1477-7819 Impact factor: 2.754
Characteristics of patients in forceps biopsy for biliary stricture
| Total ( | Malignant ( | Benign ( |
| |
|---|---|---|---|---|
| Age (years) | 68.59 ± 12.02 | 69.15 ± 11.15 | 66.00 ± 15.66 | 0.376 |
| Sex (male to female) | 53:26 | 44:21 | 9:5 | 0.806 |
| Chief complaint | ||||
| Jaundice | 52 (66 %) | 44 (68 %) | 8 (57 %) | 0.450 |
| Pain | 3 (4 %) | 2 (3 %) | 1 (7 %) | 0.470 |
| Cholangitis | 19 (24 %) | 15 (19 %) | 4 (29 %) | 0.663 |
| Stent exchange | 2 (3 %) | 2 (3 %) | 0 (0 %) | 0.506 |
| CBD dilatation | 2 (3 %) | 1 (2 %) | 1 (7 %) | 0.226 |
| Pancreatitis | 1 (1 %) | 1 (2 %) | 0 (0 %) | 0.640 |
| Total bilirubin (mg/dL) | 8.43 ± 6.33 | 9.14 ± 6.47 | 4.87 ± 4.18 | 0.025* |
| CEA (ng/mL) | 18.90 ± 57.73 | 20.58 ± 60.95 | 6.08 ± 9.78 | 0.566 |
| CA 19-9 (U/mL) | 1863.70 ± 5062.73 | 2122.58 ± 5736.81 | 88.54 ± 75.95 | 0.325 |
| ALKP (U/L) | 365.65 ± 320.33 | 367.86 ± 322.48 | 352.80 ± 324.09 | 0.892 |
| Stricture level (CBD:CHD) | 54:25 | 42:23 | 12:2 | 0.124 |
Abbreviations: CEA carcinoembryonic antigen, CA 19-9 carbohydrate antigen 19-9, ALKP alkaline phosphatase, CBD common bile duct, CHD common hepatic duct
aComparison between malignant and benign group
*P<0.05
Characteristics of patients between cholangiocarcinoma and pancreatic head cancer
| Cholangiocarcinoma ( | Pancreatic head ( |
| |
|---|---|---|---|
| Age (years) | 71.97 ± 9.72 | 65.38 ± 10.90 | 0.019* |
| Sex (male to female) | 20:14 | 19:5 | 0.104 |
| Total bilirubin (mg/dL) | 9.55 ± 6.57 | 8.49 ± 6.68 | 0.551 |
| CEA (ng/mL) | 25.61 ± 80.56 | 9.49 ± 17.80 | 0.369 |
| CA 19-9 (U/mL) | 411.09 ± 992.54 | 4441.51 ± 7462.84 | 0.017* |
| Alkaline phosphatase (U/L) | 359.34 ± 338.81 | 269.43 ± 137.32 | 0.254 |
| Stricture level (CBD:CHD) | 15:19 | 24:0 | <0.001* |
| Numbers of specimens | 4.61 ± 1.52 | 4.55 ± 1.77 | 0.895 |
| Specimens <5: ≥5 | 17:17 | 9:15 | 0.585 |
CEA carcinoembryonic antigen, CA 19-9 carbohydrate antigen 19-9
*P<0.05
Correlation between biopsy result and the final clinicopathological diagnosis
| Clinicopathological diagnosis | Biopsy result | ||
|---|---|---|---|
| Negative | Atypia | Malignant | |
| Benign ( | 14 | 0 | 0 |
| Malignant ( | |||
| Cholangiocarcinoma ( | 4 | 5 | 25 |
| Pancreatic head cancer ( | 15 | 2 | 7 |
| Colon cancer ( | 2 | 0 | 0 |
| Hepatocellular carcinoma ( | 0 | 0 | 3 |
| Gallbladder cancer ( | 0 | 1 | 0 |
| Lung cancer with liver metastasis ( | 0 | 1 | 0 |
| Total ( | 35 | 9 | 35 |
Diagnostic performance of biliary biopsy for diagnosing malignant biliary stricture
| Malignancy | Total | CCC | Pancreas | Othersa |
|---|---|---|---|---|
| Sensitivity (%) | 53.85 | 73.53 | 29.17 | 42.86 |
| Specificity (%) | 100.00 | 100.00 | 100.00 | 100.00 |
| PPV (%) | 100.00 | 100.00 | 100.00 | 100.00 |
| NPV (%) | 31.82 | 60.87 | 45.16 | 77.78 |
CCC cholangiocarcinoma, PPV positive predictive value, NPV negative predictive value
aOthers include colon cancer, hepatocellular carcinoma, gallbladder cancer, and lung cancer with liver metastasis